Previous studies have demonstrated that biomarkers linked to T cell activation, but not de novo mRNA expression, such as CD107a (5, 41) and CD154 (42–44), can be used to detect tumor-antigen specific TIL-activation. Here, LAMP1 is linked to neoplasm.